Shire plc

Infobox Company
company_name = Shire plc (formerly: Shire Pharmaceuticals Group Plc)
company_logo =
company_type = Public (lse|SHP) (Nasdaq|SHPGY) (TSX: [http://cxa.marketwatch.com/tsx/en/market/quote.aspx?symbol=US%3ASHPGY&x=10&y=6 SHPGY-Q] )
foundation = 1986
location = Basingstoke, England, UK
key_people = James Cavanaugh, Chairman
Angus Russell, CEO
industry = Pharmaceuticals
products =
revenue = $2,436 million (2007)
operating_income = $(1,379) million (2007)
net_income = $(1,451) million (2007)
num_employees =
parent =
subsid =
homepage = [http://www.shire.com www.shire.com]
footnotes =

Shire plc (lse|SHP), (Nasdaq|SHPGY), (TSX: [http://cxa.marketwatch.com/tsx/en/market/quote.aspx?symbol=US%3ASHPGY&x=10&y=6 SHPGY-Q] ) is a British manufacturer of pharmaceuticals including Adderall XR, Carbatrol, Fosrenol, and the recently released Vyvanse.

History

Shire was founded by Harry Stratford and James Murray in 1986. [http://www.shire.com/shire/assets2/HowdidShireevolveLarge.jpgHow Shire evolved] ] It was first listed on the London Stock Exchange in 1996 and in 1997 it went on to acquire Parmavene and Richmond Pharmaceutical Company. In 2007 it acquired New River Pharmaceuticals Inc, a leading US drug maker, for $2.3bn. [ [http://business.timesonline.co.uk/tol/business/industry_sectors/health/article1413738.ece Shire buys New River] ]

Operations

The Company seeks to develop and market products within advanced biotechnology for specialty physicians. Shire’s in-licensing, merger and acquisition efforts are focused on products in niche markets with strong intellectual property protection either in the US or Europe.

The Company focuses its drug research and development on the relatively common mental abnormality Attention Deficit Hyperactivity Disorder (ADHD), as is made evident by the fact that three of its currently leading medications (Adderall/Adderall XR, Daytrana, and the newly developed Vyvanse), are intended for that disorder. However the Company also works on gastrointestinal (GI) treatments, human genetic therapies (HGT) and renal diseases.

Key products are as follows: [ [http://www.shire.com/shire/Products/index.jsp?tn=4 Shire Products] ]

ADHD

* Adderall XR: All age Attention Deficit Hyperactivity Disorder
* Daytrana: Pediatric Attention Deficit Hyperactivity Disorder
* Vyvanse: All age Attention Deficit Hyperactivity Disorder

Gastrointestinal

* Lialda: Ulcerative Colitis
* Pentasa: Ulcerative Colitis

Human Genetic Therapies

* Elaprase: Hunter Syndrome
* Replagal: Fabry's disease

Renal

* Fosrenol: Hyperphosphatemia associated with End-Stage Renal Disease
* Dynepo: Anemia associated with End-Stage Renal Disease

Other

* Carbatrol: Epilepsy
* Reminyl (also sold as Razadyne): Alzheimer's Disease
* Xagrid (sold as Agrylin in the U.S.): Essential Thrombocytosis

Locations

The corporate offices are located in Basingstoke, Hampshire, UK. Other major offices are located in the United States in Wayne, Pennsylvania and Cambridge, Massachusetts. In addition, Shire owns a manufacturing site in Owings Mills, Maryland. The company has recently announced that it will move its tax domicile to Ireland. [ [http://findarticles.com/p/articles/mi_qn4158/is_20080416/ai_n25164375 Shire moves to Ireland to optimize tax] ] The move will be effected through the creation of a new holding company in Jersey, which will pay reduced tax on global earnings in Ireland. The new structure is thought to be motivated mainly by the rule that royalties on patents lodged in Ireland are tax free.

Corporate leadership

The non-executive Board Chairman is Dr. James Cavanaugh. Matthew Emmens is the Chief Executive Officer and Chairman of the Executive Committee. The President of the Human Genetic Therapies division is Sylvie Gregoire and Mike Cola is the President of Specialty Pharmaceuticals.

References

External links

* [http://www.shire.com/ Official site]
* [http://www.shire-pharma.de German pharmaceutical branch]
* [http://uk.finance.yahoo.com/q/pr?s=SHP.L Yahoo profile]